Product Offerings
Products:
Antibiotics: Coxiclin (Toltrazuril 2.5% oral solution), XT inj. (Tulathromycin 100mg/ml solution for injection)
Probiotics: Syner-Win (Probiotics + Prebiotics Synergy Effect)
Vaccines: IMMUNIS PED-M (PEDV vaccine)
WooGene B&G Co., Ltd., based in Hwaseong, South Korea, is a leading veterinary pharmaceutical manufacturer specializing in animal health solutions, including antibiotics, vaccines, probiotics, and biosecurity products. Since its establishment, the company has built a strong presence both domestically and internationally, driven by innovation, regulatory compliance, and science-backed formulations.
Core Business
WooGene B&G is dedicated to the research, development, production, and global distribution of veterinary pharmaceuticals. Its primary business spans:
- Antimicrobial agents
- Biologicals (vaccines)
- Nutritional supplements and probiotics
- Animal health biosecurity products
The company focuses on livestock health, especially swine, poultry, and ruminants, and aims to enhance productivity, disease resistance, and animal welfare through reliable veterinary products.
Product and Service Offerings
Antibiotics
- Coxiclin (Toltrazuril 2.5%) – Oral coccidiostat for the prevention and treatment of coccidiosis in poultry and swine
- XT inj. (Tulathromycin 100mg/ml) – Long-acting injectable macrolide antibiotic used for respiratory infections in swine and cattle
Probiotics
- Syner-Win – A synergistic blend of probiotics and prebiotics to enhance gut health, improve feed conversion ratios, and strengthen immunity in monogastric animals
Vaccines
- IMMUNIS PED-M – Inactivated vaccine for Porcine Epidemic Diarrhea Virus (PEDV), offering protection to piglets via maternal immunization
All products are produced in KGMP-certified manufacturing facilities (Korean Good Manufacturing Practice) with strict quality assurance protocols and batch traceability systems.
Specialisation and Core USP
WooGene B&G’s unique value proposition lies in:
- Integrated R&D capabilities, spanning from molecular biology to animal trials
- Emphasis on next-generation biologics and gut health solutions
- Commitment to antibiotic stewardship by expanding non-antibiotic product lines
- Field-proven vaccine performance with patented antigen production technologies
The company has established strong partnerships with veterinary institutions, academic bodies, and international distributors to ensure science-based product development and on-the-ground technical support.
Financials and Business Scale
As a private enterprise, WooGene B&G does not disclose detailed financial statements. However, data from industry reports and export registries indicate:
- Annual revenue estimated between USD 15–25 million
- More than 50 registered products in Korea and export markets
- State-of-the-art production facility with GMP, ISO 9001, and ISO 14001 certifications
- Presence in over 15 countries, including Vietnam, Indonesia, Thailand, Philippines, and several Middle Eastern and African nations
Shipments and Global Reach
According to import-export intelligence and product registries:
- WooGene B&G has conducted hundreds of international shipments of injectable and oral veterinary pharmaceuticals
- Key export markets: Vietnam, Thailand, Philippines, Saudi Arabia, Nigeria, Kenya
- Exported product forms include injectables, oral liquids, and powder supplements
- Company maintains product registration and local distributor partnerships in all target markets, ensuring legal and safe product entry
Target Market
The company’s products are widely used in:
- Large-scale swine and poultry operations
- Veterinary hospitals and animal health clinics
- Feed mills and integrators seeking gut health solutions
- Distributors and government veterinary programs in developing markets
WooGene B&G’s solutions are tailored for high-performance animal production systems with a focus on preventative health and sustainable productivity.
Capabilities
- Fully automated fermentation and formulation facilities
- Dedicated vaccine production unit with viral and bacterial culture lines
- In-house R&D with molecular diagnostics, immunogenicity testing, and stability studies
- Custom formulation support and private-label partnerships
- Technical service teams for on-farm and distributor training
Certifications and Compliance
WooGene B&G adheres to strict regulatory standards:
- K-GMP certified by the Korean Ministry of Agriculture, Food and Rural Affairs
- ISO 9001: Quality Management
- ISO 14001: Environmental Management
- Products registered in compliance with OIE guidelines and national veterinary regulatory agencies
- Supports antimicrobial resistance (AMR) reduction through research-backed usage protocols
Customer Testimonials
“XT inj. has become an integral part of our swine respiratory health protocol. It’s highly effective with fewer applications needed.”
— Swine Vet, Thailand
“Syner-Win helped stabilize gut health in our poultry houses. We saw visible improvements in feed conversion and mortality rates.”
— Poultry Production Manager, Vietnam
Major Achievements
- Developed patented production method for inactivated PEDV vaccine, recognized by Korean veterinary authorities
- Exported to over 15 international markets with GMP-compliant product lines
- Launched probiotic R&D pipeline targeting antibiotic-free farming systems
- Participated in leading animal health exhibitions including VIV Asia and KIST Animal Bio
- Continuous investment in global compliance and registration to expand its international footprint
With a balanced portfolio of pharmaceuticals, biologics, and nutritional products, WooGene B&G Co., Ltd. is advancing animal health with science, responsibility, and a global perspective.